Companies › MBrace Therapeutics
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| MBRC-101 anti-EPHA5 antibody-drug conjugate with monomethyl auristatin E (MMAE) payload | EPHA5 | Phase 1 | Cancer | Nov 2026 |
| MBRC-201 ADC antibody-drug conjugate | – | Phase 1 | Prostate Cancer Castration-resistant Prostate Cancer | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06014658 | MBRC-101 | Phase 1 | Cancer | Oncology | Nov 2026 |
| NCT07145255 | MBRC-201 ADC | Phase 1 | Prostate Cancer Castration-resistant Prostate Cancer | Oncology | Sep 2029 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.